Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) Profit After Tax (2016 - 2026)

Protara Therapeutics' Profit After Tax history spans 14 years, with the latest figure at -$17.8 million for Q1 2026.

  • Quarterly Profit After Tax fell 49.25% to -$17.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$63.3 million through Mar 2026, down 39.4% year-over-year, with the annual reading at -$57.4 million for FY2025, 28.8% down from the prior year.
  • Profit After Tax came in at -$17.8 million for Q1 2026, down from -$17.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$7.7 million in Q3 2022 to a low of -$39.0 million in Q4 2022.
  • The 5-year median for Profit After Tax is -$11.2 million (2024), against an average of -$13.3 million.
  • Year-over-year, Profit After Tax crashed 280.98% in 2022 and then skyrocketed 73.77% in 2023.
  • Protara Therapeutics' Profit After Tax stood at -$39.0 million in 2022, then surged by 73.77% to -$10.2 million in 2023, then decreased by 24.93% to -$12.8 million in 2024, then crashed by 35.54% to -$17.3 million in 2025, then dropped by 2.74% to -$17.8 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Profit After Tax are -$17.8 million (Q1 2026), -$17.3 million (Q4 2025), and -$13.3 million (Q3 2025).